Business Context and Reporting Period
This Form 8-K Current Report was filed by Inmune Bio, Inc. on May 17, 2019, covering events that occurred on May 16, 2019. The Company is an emerging growth company incorporated in Nevada with its principal executive offices in La Jolla, California. The report details amendments to previously executed Securities Purchase Agreements with two key executives.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to specific capital transactions:
- Transaction 1 (David Moss): Additional payment of $8,550 to adjust the purchase price of 5,000 shares from $9.00 to $10.71 per share.
- Transaction 2 (Raymond J. Tesi): Additional payment of $19,425 to adjust the purchase price of 11,100 shares from $9.00 to $10.75 per share.
- Total Additional Capital Raised: $27,975.
Material Changes Versus Prior Period
The material change reported is the amendment of purchase prices for common stock purchased by the Company's Chief Executive Officer and Chief Financial Officer. Originally reported on May 6, 2019, at $9.00 per share, the purchase prices were increased to $10.71 and $10.75 per share, respectively, resulting in immediate additional cash inflows to the Company.
Guidance, Outlook, and Risks
The filing contains no management guidance, future outlook, or discussion of risks and contingencies. It includes a standard disclaimer stating that the report does not constitute an offer to sell or a solicitation of an offer to buy shares in jurisdictions where such an offer would be unlawful without registration.
Key Facts for Investor Verification
- Verify the final adjusted purchase prices ($10.71 and $10.75) against the Company's most recent stock trading price to assess the premium paid by executives.
- Confirm the total number of shares outstanding post-transaction, as the filing references amendments to existing agreements rather than new issuances.
- Review the full text of Exhibits 10.1 and 10.2 for any additional covenants or terms attached to the amended agreements.
- Note that this filing does not provide updated financial position data; refer to the most recent 10-Q or 10-K for liquidity and operational metrics.